SEC Form 4 · accession 0001159036-15-000025
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jean-Pierre Bizzari
Director
Period of report
Jan 17, 2015
Accepted (ET)
Jan 21, 2015 · 4:53 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001159036
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 17, 2015 | A | 3,437 | $0.00 | A | 3,437 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents initial restricted stock grant upon becoming a member of the Company's Board of Directors pursuant to the Company's 2014 Directors' Compensation program. This grant will vest on the first day that the non-employee director may trade the Company's common stock in compliance with the Company's Insider Trading Policy that occurs after the six month anniversary of the date of grant.